Patent
Compounds for treating inflammatory diseases
| العنوان: | Compounds for treating inflammatory diseases |
|---|---|
| Patent Number: | 7,994,188 |
| تاريخ النشر: | August 09, 2011 |
| Appl. No: | 10/644333 |
| Application Filed: | August 20, 2003 |
| مستخلص: | The invention relates to the use of (1α.2β,4β.5α.7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane salts for preparing a pharmaceutical composition for the prevention and treatment of diseases associated with inflammation. |
| Inventors: | Disse, Bernd (Mainz, DE) |
| Assignees: | Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim am Rhein, DE) |
| Claim: | 1. A method for treating an inflammatory component of cystic fibrosis, which method comprises administering, via inhalation, a formulation wherein the active substance consists of a therapeutically effective amount of a salt of tiotropium, and, optionally, physiologically acceptable excipients, and wherein the salt of tiotropium provides an anti-inflammatory activity. |
| Claim: | 2. The method as recited in claim 1 wherein the tiotropium salt has an anion selected from chloride, bromide, iodide, methanesulphonate, paratoluenesulphonate and methylsulphate. |
| Claim: | 3. The method as recited in claim 2 wherein the anion of the tiotropium salt is methanesulphonate, chloride, bromide or iodide. |
| Claim: | 4. The method as recited in claim 3 wherein the anion of the tiotropium salt is methanesulphonate or bromide. |
| Claim: | 5. The method as recited in claim 3 wherein the anion of the tiotropium salt is bromide. |
| Claim: | 6. The method of claim 1 , wherein the salt of tiotropium is administered via inhalation in a formulation selected from powders for inhalation, metered-dose aerosols containing propellant gas and propellant-gas-free inhalable solutions. |
| Claim: | 7. The method of claim 6 , wherein the formulation is an inhalable powder which contains the tiotropium salt in admixture with a suitable physiologically acceptable excipient selected from monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, salts, and mixtures thereof. |
| Claim: | 8. The method of claim 6 , wherein the formulation is an inhalable aerosol containing a propellant gas, which contains the tiotropium salt in dissolved or dispersed form. |
| Claim: | 9. The method of claim 8 , wherein the propellant gas is a hydrocarbon or halohydrocarbon gas. |
| Claim: | 10. The method of claim 8 , wherein the propellant gas is n-butane, isobutane, or a fluorinated methane, ethane, propane, butane, cyclopropane or cyclobutane. |
| Claim: | 11. The method of claim 8 , wherein the propellant gas is TG134a, TG227 or a mixture thereof. |
| Claim: | 12. The method of claim 8 , wherein the inhalable aerosol further comprises one or more other ingredients selected from co-solvents, stabilizers, surfactants, antioxidants, lubricants and pH adjusters. |
| Claim: | 13. The method of claim 6 , wherein the formulation is a propellant-free inhalable solution which further comprises a solvent selected from water, ethanol or a mixture of water and ethanol. |
| Claim: | 14. The method of claim 13 , wherein the pH of the propellant-free inhalable solution is 2-7. |
| Claim: | 15. The method of claim 13 , wherein the propellant-free inhalable solution further comprises a co-solvent which contains hydroxyl groups or other polar groups. |
| Claim: | 16. The method of claim 15 , wherein the cosolvent is an alcohol or glycol. |
| Claim: | 17. The method of claim 15 , wherein the propellant-free inhalable solution further comprises at least one surfactant, stabilizer, complexing agent, antioxidant, preservative, flavoring, pharmacologically acceptable salt or vitamin. |
| Claim: | 18. The method of claim 13 , wherein the propellant-free inhalable solution contains only benzalkonium chloride and sodium edetate in addition to the active substance and the solvent. |
| Claim: | 19. The method of claim 13 , wherein the propellant-free inhalable solution is a concentrate or a sterile inhalable solution ready for use. |
| Claim: | 20. The method of claim 6 , wherein the formulation further comprises, as complexing agent, editic acid or a salt of editic acid. |
| Claim: | 21. The method of claim 6 , wherein the formulation further comprises, as complexing agent, sodium edetate. |
| Current U.S. Class: | 514/291 |
| Patent References Cited: | 5250286 October 1993 Skupin 5610163 March 1997 Banholzer et al. 5824669 October 1998 Garvey et al. 5948792 September 1999 Tsuchiya et al. 6150418 November 2000 Hochrainer et al. 6197762 March 2001 Garvey et al. 6537524 March 2003 Hassan et al. 6653313 November 2003 Kawamura et al. 6919069 July 2005 Akehurst et al. 2001/0008632 July 2001 Freund et al. 2002/0099023 July 2002 Boucher, Jr. 2002/0111495 August 2002 Magee et al. 2002/0122773 September 2002 Pairet et al. 2002/0193394 December 2002 Disse WO 98/00119 January 1998 WO 98/27959 July 1998 WO 99 66944 December 1999 WO 00/47200 August 2000 WO 01/10427 February 2001 WO 01/12167 February 2001 WO 01/78739 October 2001 |
| Other References: | Definition of bronchitis and chronic bronchitis from On-line Medical dictionary, Database Google.com. cited by examiner Definition of bronchitis and chronic bronchitis from merriam-Webster (Medline plus) on-line dictionary, Database Google.com. cited by examiner F.P.V. Maesen, J.J. Smeets, T.J.H. Sledsens, F.D.M. Wald, and P.J.G. Cornelissen, Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD), Eur. Respir J, 1995, 8, 1506-1513. cited by examiner P.M. O'Byrne and D.S.Postma, The Many Faces of Airway Inflammation, Am. j. Respir Crit. Care. Med. vol. 159, pp. s41-s66, 1999. cited by examiner Gerd J. Cropp, Effectiveness of bronchodilators in cystic fibrosis, The American Journal of Medicine, vol. 100, Supplement 1, Jan. 29, 1996, S19-S29. cited by examiner Peter J. Barnes, The Pharmacological Properties of Tiotropium, Chest, 117(2) Februaty, 2000, 63S-66S. cited by examiner Littner, M. R. et al; “Long-Acting Bronchodilation with Once-Daily Dosing of Tiotropium (Spiriva) in Stable Chronic Obstructive Pulmonary Disease”; Am J Resp and Critical Care Med; Am Lung Assn,; 161(41) 2000; pp. 1136-1142; XP001148373. cited by other Lasserson, T. et al; “Anticholinergic Therapy For Bronchiectasis”; Cochrane Database of Systematic Reviews; 4; 2001; XP008019810. cited by other Rogers, D. F.; “Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy”; Monaldi Archives for Chest Disease, 55(4); 2000, pp. 324-332; XP008019816. cited by other Witek T. J., JR: “Anticholinergic Bronchodilators.” Respiratory Care Clinics of North America. United States Dec. 1999, Bd. 5, Nr. 4, Dec. 1999 pp. 521-536 XP008014468, ISSN: 1078-5337. cited by other Wegner, Craig, Novel Mechanistic Targets for the Treatment of Sub-Acute and Chronic Bronchitis, Current Pharmaceutical Design, 2001, vol. 7, pp. 199-212, full text, especially p. 201. cited by other Peter Barnes, Novel Approaches and Targets for Treatment of Chronic Obstructive Pulmonary Disease, American Journal of Respiratory and Critical Care Medicine, vol. 160(5), Nov. 1999, pp. S72-S79. cited by other Leckie et al., Novel Therapy for COPD., Database CAPLUS, AN 2000:16639, abstract only, Expert Opinion on Investigational Drugs, 2000, vol. 9(1), pp. 3-23. cited by other “bronchitis”, The American Heritage Dictionary of the English Language, Foruth Edition 2000. cited by other Barnes, Peter, Muscarinio receptor subtypes in airways, Database GOOGLE.com abstract alone, Euroconference, Apr. 1998. cited by other Product information: Tiotropium Bromide (SPIRIVA TM), Database GOOGLE.com, Drugs of the future, 2000, vol. 25(7):693-699. cited by other Petty, T., The Rising Epidemic COPD in Women, Database GOOGLE.com, 1999, vol. 2(12), pp. 942-953. cited by other |
| Assistant Examiner: | Samala, Jagadishwar |
| Primary Examiner: | Hartley, Michael G |
| Attorney, Agent or Firm: | Morris, Michael P. Petka, Wendy A. |
| رقم الانضمام: | edspgr.07994188 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |